Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.57 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.55 |
| ▸ | HTR3B | O95264 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915560 | 0.86 | DRD2 (0.59) | DRD2DRD3SLC6A2SLC6A4ADRA1D | |
| SCHEMBL4913485 | 0.86 | ALDH1A1 (0.60) | DRD2DRD3ADRA1DADRA1AADRA1B | |
| SCHEMBL4913476 | 0.86 | ALDH1A1 (0.60) | DRD2DRD3ADRA1DADRA1AADRA1B | |
| SCHEMBL4915562 | 0.86 | DRD2 (0.59) | DRD2DRD3SLC6A2SLC6A4ADRA1D | |
| SCHEMBL7816498 | 0.84 | DRD2 (0.50) | DRD2SLC6A2SLC6A4ALDH1A1GFER | |
| SCHEMBL13644130 | 0.83 | DRD2 (0.60) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL20129688 | 0.82 | DRD2 (0.62) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL16367745 | 0.82 | DRD2 (0.54) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL20129685 | 0.80 | DRD2 (0.64) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL16367748 | 0.80 | ADRA1D (0.63) | DRD2DRD3SLC6A2SLC6A4ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6353002-B2 | DIOXINOINDOLE AND THIENOBENZODIOXIN COMPOUNDS WHICH ARE HT3 RECEPTOR ANTAGONISTS AND ARE USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | disclosed |
| EP-1087964-A1 | N-BENZODIOXANYLMETHYL-1-PIPERIDYL-METHYLAMINE COMPOUNDS HAVING AFFINITY FOR 5-HT RECEPTORS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-04-04 | — | — | EP | disclosed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-0717739-B1 | 1,4-Benzodioxane derivatives having affinity for D2 receptors and utility in the treatment of psychoses | KNOLL AG (DE) | 2000-03-29 | — | — | EP | disclosed |
| EP-0966470-A1 | DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999062902-A1 | N-BENZODIOXANYLMETHYL-1-PIPERIDYL-METHYLAMINE COMPOUNDS HAVING AFFINITY FOR 5-HT RECEPTORS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-12-09 | — | — | WO | disclosed |
| WO-1998040386-A1 | DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
| US-5767116-A | TREATING PSYCHOSES | KNOLL ATKIENGESELLSCHAFT (DE) | 1998-06-16 | — | — | US | disclosed |
| EP-0717739-A1 | BICYCLIC AROMATIC COMPOUNDS AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007274-A1 | BICYCLIC AROMATIC COMPOUNDS AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008903-A1 | Therapeutic agents | GPR119, SNCA, HTR2B | DRD2 94/4885DRD3 159/4885HTR3E 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.